AD	
111	

Award Number: DAMD17-01-1-0061

TITLE: Intermittent Ultrasound Imaging of Prostate Cancer

PRINCIPAL INVESTIGATOR: Ethan Joseph Halpern, M.D.

CONTRACTING ORGANIZATION: Thomas Jefferson University

Philadelphia, Pennsylvania 19107

REPORT DATE: August 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquareters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Pagerwork Reduction Project (0704-0188) Washington, DC 20503.

to the Office of Management and Budget, Paperwork						
1. AGENCY USE ONLY (Leave blank)		3. REPORT TYPE AN				
A TITLE AND CURTITIE	August 2002	Annual (1 Aug				
4. TITLE AND SUBTITLE				5. FUNDING NUMBERS		
Intermittent Ultrasound Imaging of Prostate Cancer		DAMD17-01	DAMD17-01-1-0061			
6. AUTHOR(S)			7			
Ethan Joseph Halpern	ı, M.D.					
7. PERFORMING ORGANIZATION NAM	ME(S) AND ADDRESS(ES)		O DEDECIDADA	IC ODCANIZATION		
Thomas Jefferson Uni			8. PERFORMING ORGANIZATION REPORT NUMBER			
Philadelphia, Pennsy	-					
Filliadelphia, Pellisy	Ivailla 19107					
E-Mail: ethan.halpern@mail.tju.ed	du					
,						
Q SPONSORING (MONITORING ACT	NOV NAME (C) AND ADDRESS (C)					
9. SPONSORING / MONITORING AGE	NCY NAME(S) AND ADDRESS(ES	9)		ING / MONITORING REPORT NUMBER		
U.S. Army Medical Resear	ch and Materiel Comma	ınd	Adento	TEI OTT HOMBEN		
Fort Detrick, Maryland			1			
11. SUPPLEMENTARY NOTES						
12a. DISTRIBUTION / AVAILABILITY S	TATEMENT			12b. DISTRIBUTION CODE		
Approved for Public Rele	ase; Distribution Unl	imited				
13. ABSTRACT (Maximum 200 Words			1			
This study proposed to excontrast agent in 300 sul						
of prostate cancer. Altho	ough the grant poriod	bogan 8/1/200	braer to im	prove the detection		
commenced on 10/1/2001.	Retween 10/15/2001 a	$\frac{1}{2}$	total of 1	03 subjects provided		
informed consent. Labora						
on all 103 subjects (inc.						

contrast agent in 300 subjects over a period of 3 years in order to improve the detection of prostate cancer. Although the grant period began 8/1/2001, patient recruitment actually commenced on 10/1/2001. Between 10/15/2001 and 7/31/2002 a total of 103 subjects provided informed consent. Laboratory blood tests (PSA) and ultrasound evaluations were completed on all 103 subjects (including the ultrasound interpretation worksheet of the primary reviewer). An independent blinded reader has completed review of the first 47 subjects. Pathological review for the presence and grade of cancer has been completed for all 103 subjects. CD31 staining for microvissel density is in progress. Microvessel density counting will begin in August 2002. All available data has been entered into a computer database using an Excel spreadsheet. A preliminary analysis of the data from the first 56 subjects was incorporated into an abstract that has been accepted for presentation at the 60<sup>th</sup> annual meeting of the Mid-Atlantic section of the American Urological Association (see appendix). Based upon the current rate of recruitment (10 patients/month), study recruitment will require an additional 20 months. If the end date for the study is extended to 9/31/04, the study protocol is progressing on target.

14. SUBJECT TERMS prostate cancer, PSA,	ultrasound		15. NUMBER OF PAGES
·			16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Unlimited

# **Table of Contents**

Cover	1
SF 298	2
Introduction	4
Body	5
Key Research Accomplishments	5
Reportable Outcomes	5
Conclusions	5
Appendices	6

## **INTRODUCTION:**

The objective of this study is to utilize ultrasound imaging with intravenous infusion of a microbubble contrast agent to improve the detection of prostate cancer, and to identify those cancers which are clinically significant. Over a three year period, three hundred subjects with suspected cancer of the prostate are to be enrolled. These patients will be imaged with conventional and intermittent ultrasound both before and after administration of the contrast agent. Based upon a comparison of ultrasound findings with biopsy results, this study will attempt to demonstrate that intermittent ultrasound imaging with a contrast agent results in improved detection of prostate cancer. Furthermore, ultrasound findings with the contrast agent are to be correlated with Gleason score and PSA in order to determine whether intermittent imaging can selectively identify clinically significant cancers.

### BODY:

#### Statement of Work tasks:

- #1 Ultrasound contrast studies: One hundred and three subjects have been recruited into the study to date. Each subject has provided written informed consent and was evaluated with the required laboratory studies (PSA) prior to participation in the ultrasound contrast protocol. The examining physician (Dr. Ethan Halpern) has completed an ultrasound image interpretation worksheet for each of these subjects. Because of paperwork delays, patient recruitment began in October 2001, two month after the start date of the grant. Assuming that the end date of the study is extended by two months to 9/31/2004, this portion of the study is progressing on target.
- #2 Pathologic evaluation: Specimens from all 103 subjects have been evaluated by standard pathologic evaluation. A pathology interpretation worksheet has been completed by our pathology consultant (Dr. Peter McCue). Approximately one-third of the subjects were found to have cancer. Additional tissue sections from each biopsy block have been cut for CD31 staining. Technical problems were encountered with the microvessel density counting system. These have now been fixed, and microvessel density counting of specimens will commence in August 2002.
- #3 Database entry: A database has been established, and all ultrasound and pathology data available to date have been entered by the research coordinator.
- #4 Interim statistical evaluation: planned for month 13 will be performed in October 2002 (because of the two month delay in starting patient recruitment).
- #5 Consensus interpretations: blinded reviews of the ultrasound studies are performed by a second reader (Dr. Stephen Strup). Blinded reads have been completed for the first 47 cases.
- #6 Publications: a preliminary abstract for the first 56 subjects was accepted for presentation at the annual meeting of the mid-Atlantic section of the American Urological Association.

## KEY RESEARCH ACCOMPLISHMENTS:

- Successful infusion of ultrasound contrast in 103 subjects
- Visible vascular enhancement within the prostate of all subjects studied to date
- Detection of three-fourths of cancer foci based upon contrast enhancement to date

REPORTABLE OUTCOMES: one abstract accepted for presentation (see attached – page 6).

### **CONCLUSIONS:**

Intravenous infusion of a microbubble contrast agent provides sonographically visible enhancement of the prostate. This enhancement can be used to guide biopsy of the prostate into areas of increased vascular flow. In our study, targeted biopsies of areas with increased blood flow detected approximately three-fourths of cancers found in our population. In the initial 56 subjects, several cancers were not identified at the apex of the gland based upon contrast-enhanced flow patterns (see abstract). Follow-up is required to determine whether this technique detects all "significant cancers", or whether the contrast technique misses important cancers.

# Abstract accepted for presentation at the Mid-Atlantic AUA meeting – 10/2002

Comparison of an unrestricted targeted approach to a sextant approach for contrast-enhanced Biopsy of a Prostate

Ethan J. Halpern, MD<sup>1</sup> Ferdinand Frauscher, MD<sup>1</sup> Stephen E. Strup, MD<sup>2</sup> Leonard G. Gomella, MD<sup>2</sup>

Purpose: Sextant biopsy of the prostate systematically samples the base, mid-gland and apex. Recent studies have demonstrated improved detection of prostate cancer based upon targeted biopsy with microbubble contrast agents. Our study evaluated cancer detection with two different contrast-enhanced biopsy strategies: an unrestricted targeted approach that focused on the most suspicious areas in the outer gland, and a modified sextant approach that targeted the most suspicious area within each sextant.

Methods: Fifty six subjects with an elevated PSA (> 4ng/ml) or abnormal digital rectal examination were evaluated by transrectal sonography during infusion of a microbubble contrast agent (Imavist – Alliance Pharmaceuticals). Sonography was performed with the Sonoline Elegra (Siemens Medical Systems) using a 6.5MHz end-fire transducer. Up to four unrestricted targeted biopsy cores were directed toward the most suspicious areas of the outer gland during contrast-enhanced harmonic gray scale and Doppler imaging. Six additional biopsy cores were obtained in a modified sextant distribution to target the most suspicious area in each sextant. Each sextant with no suspicious area was sampled with a laterally directed core.

Results: Cancer was detected in 77 biopsy cores from 19 of 56 subjects (34%). Cancer was found in 18% (34/193) of unrestricted targeted cores and in 13% (43/336) of targeted sextant cores. Of 19 subjects with cancer, 15 were detected by both techniques. Three subjects were detected only by targeted sextant biopsy while 1 subject was detected only by unrestricted targeted biopsy. The 3 subjects missed by unrestricted targeted biopsy included two Gleason 6 cancers (at right apex and left apex) and one Gleason 8 cancer (at right apex). While 42% (18/43) of positive targeted sextant cores were obtained at the gland apex, only 18% (6/34) of positive unrestricted targeted cores were obtained from the gland apex. Only 12% (23/193) of unrestricted targeted biopsies were directed to the apex.

Conclusion: Although the "per-core" cancer detection rate of unrestricted targeted biopsy was slightly higher when compared to the targeted sextant approach, the unrestricted technique missed cancers at the apex of the prostate. The low proportion of biopsy cores targeted to the apex suggests that contrast enhancement is less conspicuous at the apex. In order to maximize cancer detection, we recommend that any targeted biopsy strategy should include cores at the apex of the prostate.